Effect of thyroid hormone status and concomitant medication on statin induced adverse effects in hyperlipidemic patients

Pharmazie

Volumn 69, Issue 6, 2014, Pages 420-423

  Berta, E ^a   Harangi, M ^a   Zsiros N ^a   Nagy, E V ^a   Paragh, G ^a   Bodor, Miklos ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIOTHYRONINE; MEVINOLIN; ROSUVASTATIN; SIMVASTATIN; THYROID HORMONE; THYROTROPIN; THYROXINE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFICACY; DRUG METABOLISM; DRUG TRANSFORMATION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLIPIDEMIA; HYPERTHYROIDISM; HYPOTHYROIDISM; LIVER DISEASE; MAJOR CLINICAL STUDY; MYOPATHY; RISK REDUCTION;

AGED; CHOLESTEROL; CHOLESTEROL, LDL; CREATINE KINASE; CYTOCHROME P-450 ENZYME SYSTEM; ELECTROCHEMISTRY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; MUSCULAR DISEASES; THYROID FUNCTION TESTS; THYROID GLAND; THYROID HORMONES; THYROTROPIN;

EID: 84903273419     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2014.3909R     Document Type: Article

References (29)

1. Alsheikh-Ali AA, Karas RH (2005) Adverse events with concomitant amiodarone and statin therapy. Prevent Cardiol 8: 95-97.
2. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirrby A, Sourjina T, Peto R, Collins R, Simes R (2005) Efficacy and safety of cholesterol-lowering treatment; prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267-1278.
3. Bailey KM, Romaine SPR, Jackson BM, Farrin AJ, Efthymiou M, Barth JH, Copeland J, McCormack T, Whitehead A, Flather MD, Samani NJ, Nixon J, Hall AS, Balmforth AJ (2010) Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction. Circ Cardiovas Gen 3: 276-285.
4. Beyer IW, Karmali R, Demeester-Mirkine N, Cogan E, Fuss MJ (1998) Serum creatine kinase levels in overt and subclinical hypothyroidism. Thyroid 8: 1029-1031. (Pubitemid 28551083)
5. Duntas LH (2002) Thyroid disease and lipids. Thyroid 12: 287-293.
6. Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286: 487-491. http://www.fda.gov/ Drugs/DevelopmentApprovalProcess/Development Resources/DrugInteractionsLabeling/ ucm080499.htm, accessed 2013.10.19.
7. Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39: 1-17.
8. Harris R, Jang G, Tsunoda S (2003) Dietary effects on drug metabolism and transport. Clin Pharmacokinet 13: 1071-1088.
9. Ho MT, Kelly EJ, Bodor M, Bui T, Kowdley KV, Ho RJ (2011) Novel cytochrome P450-2D6 promoter sequence variations in hepatitis C positive and negative subjects. Annu Hepatol 10: 327-332.
10. Huang SM, Temple R (2008) Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin Pharmacol Ther 84: 287-284.
11. Huang SM, Temple R, Throckmorton DC, Lesko LJ (2007) Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 81: 298-304. (Pubitemid 46174829)
12. Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Al HS, Baweja RK, Burckart GJ, Chung S, Colangelo P, Frucht D, Green MD, Hepp P, Karnaukhova E, Ko HS, Lee JI, Marroum PJ, Norden JM, QiuW, Rahman A, Sobel S, Stifano T, Thummel K,Wei XX, Yasuda S, Zheng JH, Zhao H, Lesko LJ (2008) Newera in drug interaction evaluation: US food and drug administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48: 662-670. (Pubitemid 351713150)
13. Jarin C, Ute MK, Rachel MM, Lawrence MS, Paul FH (2000) Mechanismbased inactivation of cytochromes P450 2B1 and P450 2B6 by 2-phenyl-2 (1-piperidinyl) propane. Drug Metab Dispos 8: 905-911.
14. Klein I, Danzi S (2007) Thyroid disease and the heart. Circulation 116: 1725-1735. (Pubitemid 47537847)
15. Madariaga MG, Gamarra N, Dempsey S, Barsano CP (2002) Polymyositislike syndrome in hypothyroidism: review of cases reported over the past twenty-five years. Thyroid 12: 331-336.
16. Li AP, Maurel P, Gomez-lechon MJ, Cheng LC, Jurima-Romet M (1997) Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chem Biol Interact 2: 5-16
17. McConnachie L, Bodor M, Kowdley K, Levy A, Tung B, Thummel K, Phillips B, Bajpai M, Chi V, Esmay JD, Shen DD, Ho RJY;1; (2004) Human liver cytochrome P450 2D6 genotype, full-length messenger ribonucleic acid, and activity assessed with a novel cytochrome P450 2D6 substrate. Clin Pharmacol Ther 75: 282-297.
18. Nichols GA, Koro CE (2007) Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther 29: 1761-1770. (Pubitemid 47494553)
19. Nicholson TE, Renton KW (1999) Modulation of cytochrome P450 by inflammation in astrocytes. Brain Res 8: 12-18. (Pubitemid 29222899)
20. Paolini M, Biagi GL, Cantelli-Forti G (1999) The many consequences of chemical- and genetic-based modulation of drug metabolizing enzyme activities. Life Sci 8: 75-79.
21. Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C (2002) ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 40: 567-572. http://www.pharmindexonline.hu/, accessed 2013.10.19.
22. Rosenson RS (2004) Statins in atherosclerosis: lipid-lowering agents with antioxidant capabi-lities. Atherosclerosis 173: 1-12.
23. Rush J, Danzi S, Klein I (2006) Role of thyroid disease in the development of statin-induced myopathy. Endocrinologist 16: 279-285. (Pubitemid 44465658)
24. Shitara Y, Sugiyama Y (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112: 71-105. (Pubitemid 44301483)
25. Sikka R, Magauran B, Ulrich A, ShannonM(2005) Bench to bedside: pharmacogenomics, adverse drug interactions, and the cytochrome P450 system. Acad Emerg Med 12: 1227-1235. (Pubitemid 41681176)
26. Tan KC, Shiu SW, Kung AW (1998) Effect of thyroid dysfunction on high-density lipoprotein subfraction metabolism: roles of hepatic lipase and cholesteryl ester transfer protein. J Clin Endocrinol Metab 83: 2921-2924. (Pubitemid 28493799)
27. Olson BR, Klein I, Benner R, Burdett R, Trzepacz P, Levey GS (1991) Hyperthyroid myopathy and the response to treatment. Thyroid 1: 137-41.
28. Vanderpump MPJ, Tunbridge WMG, French JM, Appleton D, Bates D, Clark F, Grimley Evans J, Hasan DM, Rodgers H, Tunbridge F, Young ET (1995) The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol 43: 55-68.
29. Wijnen PA,Op den Buijsch RA, Drent M,Kuijpers PM, Neef C, Bast A, Bekers O,Koek GH (2007) Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms. Aliment Pharmacol Ther. 26 Suppl. 2: 211-219. (Pubitemid 350233335)